Financials in USD. Standardized financial statements.
A compact view of how PharmaRoth Labs, Inc. turns revenue into operating income and net income.
| Metric | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2010 | FY 2009 | FY 2008 | FY 2007 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $181,563 | $263,458 | $86,977 | $529,047 | $153,892 | $0 | $0 | $0 | $0 |
| Revenue Growth? | -31.1% | +202.9% | -83.6% | +243.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $108,938 | $155,440 | $60,052 | $212,629 | $119,666 | $0 | $0 | $0 | $0 |
| Gross Profit? | $72,625 | $108,018 | $26,925 | $316,418 | $34,226 | $0 | $0 | $0 | $0 |
| Gross Margin? | +40.0% | +41.0% | +31.0% | +59.8% | +22.2% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $164,201 | $340,923 | $396,935 | $608,955 | $460,939 | $19,655 | $13,150 | $34,900 | $10,700 |
| Operating Income? | -$91,576 | -$232,905 | -$370,010 | -$292,537 | -$426,713 | $230,345 | -$13,150 | -$34,900 | -$10,700 |
| EBITDA? | -$91,576 | -$232,905 | -$370,010 | -$292,077 | -$424,600 | -$269,655 | -$13,150 | -$34,900 | -$10,700 |
| Income Before Tax | -$91,576 | -$232,905 | -$370,010 | -$292,537 | -$426,713 | -$19,655 | $0 | $0 | -$10,700 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $250,000 | $13,150 | $34,900 | $0 |
| Net Income? | -$91,521 | -$232,846 | -$369,781 | -$290,972 | -$425,198 | -$269,655 | -$13,150 | -$34,900 | -$10,700 |
| EPS? | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.01 | $-0.00 | $-0.00 | $-0.00 |
| Diluted EPS? | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.01 | $-0.00 | $-0.00 | $-0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality